Clinical trial · Interventional
Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
The Role of Quantitative Contrast-Enhanced Ultrasound in Yttrium-90 (90Y) Radioembolization of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Accrual issue
Summary
Brief summary (as posted)
This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Device | — | UNRESOLVED |
| Dynamic Contrast-Enhanced Ultrasound Imaging | Device | — | UNRESOLVED |
| Perflutren Lipid Microspheres | Drug | — | UNRESOLVED |
| Positron Emission Tomography | Device | — | UNRESOLVED |
| Sulfur Hexafluoride Lipid Microspheres | Drug | — | UNRESOLVED |
| Yttrium-90 (90Y) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (CEUS)
- description
- Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
- interventionNames
- Drug: Perflutren Lipid Microspheres
- Drug: Sulfur Hexafluoride Lipid Microspheres
- Device: Dynamic Contrast-Enhanced Ultrasound Imaging
- Device: Positron Emission Tomography
- Device: Computed Tomography
- Biological: Yttrium-90 (90Y)
Primary outcomes (1)
- measure
- Local tumor response to therapy
- timeFrame
- Up to 24 weeks
- description
- Will be assessed by modified Response Evaluation Criteria in Solid Tumors criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients scheduled for 90Y radioembolization for HCC as part of their standard of care Exclusion Criteria: * Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency \[RF\] ablation or transarterial chemoembolization \[TACE\]) * Pregnant or nursing * Known cardiac shunt * Known pulmonary hypertension * History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason * History of hypersensitivity to iodinated contrast agent * Cannot consent for himself or herself
References
Publications (0)
Data not yet available